Sign in

    Ash Birma

    Research Analyst at UBS

    Ash Birma is an Executive Director and Equity Research Analyst at UBS, specializing in coverage of the European and UK real estate sectors with a focus on listed property companies such as Land Securities, British Land, and SEGRO. Throughout his career at UBS, Birma has established a solid track record for deep sector insights and actionable investment recommendations, earning positive recognition among institutional investors. He began his analyst career after gaining previous financial and analytical experience at other institutions, joining UBS in 2016 and progressively advancing to his current leadership post where he leads coverage of major REITs and real estate investment vehicles. Birma holds key UK financial certifications and is registered with the FCA, underscoring his expertise and commitment to regulatory standards in financial analysis.

    Ash Birma's questions to AVADEL PHARMACEUTICALS (AVDL) leadership

    Ash Birma's questions to AVADEL PHARMACEUTICALS (AVDL) leadership • Q2 2025

    Question

    An analyst from UBS, on behalf of Ash Birma, asked about the ongoing antitrust case against Jazz Pharmaceuticals. The questions focused on how Avadel substantiates the 1.5-year market entry delay and the implications of the lack of a summary judgment resolution.

    Answer

    CEO Gregory Divis declined to comment on specific matters related to the ongoing litigation, stating that details would become clearer closer to the scheduled jury trial, which is set to begin in under three months.

    Ask Fintool Equity Research AI